Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00541216

Ephedrine for the Treatment of Congenital Myasthenia

Sponsor: Hadassah Medical Organization

Conditions Myasthenic Syndromes, Congenital

Interventions Ephedrine

Updated 6 times since 2017 Last updated: Oct 9, 2007 Started: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Myasthenic Syndromes, Congenital, this trial is ongoing. The trial is conducted by Hadassah Medical Organization and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

Status: Enrolling By Invitation → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE1_PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hadassah Medical Organization

Data source: Hadassah Medical Organization

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel